The Manufacturers Life Insurance Company Trims Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

The Manufacturers Life Insurance Company lessened its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,247 shares of the company’s stock after selling 226 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in TransMedics Group were worth $1,138,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group in the fourth quarter worth about $31,000. Hager Investment Management Services LLC bought a new stake in shares of TransMedics Group during the 4th quarter worth approximately $33,000. Sachetta LLC purchased a new position in TransMedics Group during the 4th quarter valued at $40,000. AlphaQuest LLC purchased a new position in TransMedics Group during the 4th quarter valued at $52,000. Finally, Arcadia Investment Management Corp MI bought a new position in TransMedics Group in the 4th quarter valued at $72,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on TMDX shares. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $125.00 target price (up from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Finally, Oppenheimer boosted their price target on TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $126.70.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the transaction, the director now owns 732 shares of the company’s stock, valued at $84,641.16. The trade was a 89.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Price Performance

NASDAQ TMDX opened at $122.11 on Wednesday. The company has a market cap of $4.13 billion, a PE ratio of 129.91 and a beta of 1.91. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm’s 50 day moving average price is $80.69 and its 200-day moving average price is $75.38.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue was up 48.2% compared to the same quarter last year. During the same period last year, the business posted $0.35 EPS. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.